We are using the gut microbiome to end cancer.
Public company, workplace, funding, and market signals
Persephone Biosciences is a San Diego-based biotechnology company that combines microbiome research and synthetic biology to commercialize infant/toddler synbiotics and related microbiome-driven health solutions. Its flagship consumer product is the Daily Synergistic Synbiotic (Bloom for infants and Thrive for toddlers), a probiotic-plus-prebiotic powder designed to replenish missing Bifidobacterium and support gut, immune, and developmental health.
Primary product
Daily Synergistic Synbiotic (Bloom for infants 0-12 months; Thrive for toddlers 12-36 months)
Founded
2017
Headquarters
10835 Road to the Cure, Suite 150, San Diego, CA 92121, United States
Team size
11-50
Industry
Biotechnology Research
Sub-industry
Microbiome therapeutics / infant synbiotics
Offices
0 jobs at Persephone Biosciences
Check back later for new openings
Business model
Stage
seed
Total raised
$15.1M
Latest round
Seed · Jul 2022
Latest amount
$15M
Leadership
CEO & Co-Founder
CTO & Co-Founder
Chief Medical Advisor
Veronique Riethuisen
Board Member and CBO
Gillian Snyder
Head of Marketing
Shaun Singer
Director of Poop for the Cure
Bryce Jarman, PhD
Head of Product Development
Head of Computational Biology
Daniel Bradbury
Chairman, Board of Directors
Investors
Mission-driven and science-first, with a cross-functional team spanning biotech, clinical development, and direct-to-consumer commercialization. Public copy emphasizes rigorous research, safety testing, and translating microbiome science into consumer health products.
Visa sponsorship
Limited
Compensation
No public salary bands were posted on the careers page. Third-party visa data shows historical H-1B sponsorship and a 2024 average proffered salary around $65K for filed roles, while the company had no open jobs listed on its careers page/Y Combinator listing at the time of review.
Benefits
Pricing
Direct-to-consumer retail pricing with one-time purchase and subscription options; Bloom and Thrive were publicly listed at $74.95 one-time or $64.95/month subscription.
Differentiators
Technology
Customers
Competitors
Estimated revenue
~$500K-$1M (third-party estimate, 2024)
Estimated monthly visits
6.8K
Traffic estimate as of Oct 2024
GlobeNewswire · Dec 2025
Reported a publication in Cell Host & Microbe showing modern infant microbiomes are deficient in key Bifidobacterium and highlighting clinical strategies to restore them; the company reiterated its infant synbiotic launch and research framing.
BioSpace · Nov 2025
ARTEMIS topline results reported tolerability, colonization, and improved sleep outcomes in toddlers after 30 days, strengthening the evidence base for the company’s infant/toddler synbiotic.
GlobeNewswire · Nov 2025
Released topline results from the Kroger Health collaboration, showing diet/medical nutrition therapy could improve microbiome composition and move participants between enterotypes.
GlobeNewswire · Sep 2025
Consumer launch announcement for Bloom/Thrive, including pricing, formulation details, and the company’s explanation that the product is designed to restore missing gut microbes in babies.
NutraIngredients · Mar 2025
Previewed the company’s upcoming consumer launch and described its age-specific infant and toddler synbiotic strategy, clinical positioning, and differentiators.